Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis

Driven by access to better drugs, on average, newly diagnosed multiple myeloma patients have over 10 years overall survival. Using modern combination therapies – with or without the addition of high-dose melphalan and autologous stem cell transplantation – up to 80% of patients reach a complete resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Landgren, Ola, Devlin, Sean, Boulad, Mathieu, Mailankody, Sham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571752/
https://www.ncbi.nlm.nih.gov/pubmed/27595280
http://dx.doi.org/10.1038/bmt.2016.222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571752/
https://www.ncbi.nlm.nih.gov/pubmed/27595280
http://dx.doi.org/10.1038/bmt.2016.222

Ejemplares similares